HIV latency is the foremost barrier to clearing HIV infection from patients. Reactivation of latent HIV-1 represents a promising strategy to deplete these viral reservoirs. Here, we report a novel approach to reactivate latent HIV-1 provirus using artificially designed transcription activator-like effector (TALE) fusion proteins containing a DNA-binding domain specifically targeting the HIV-1 promoter and the herpes simplex virus-based transcriptional activator VP64 domain. We engineered four TALE genes (TALE1–4) encoding TALE proteins, each specifically targeting different 20-bp DNA sequences within the HIV-1 promoter, and we constructed four TALE-VP64 expression vectors corresponding to TALE1–4. We found that TALE1-VP64 effectively reactivated HIV-1 gene expression in latently infected C11 and A10.6 cells. We further confirmed that TALE1-VP64 reactivated latent HIV-1 via specific binding to the HIV-LTR promoter. Moreover, we also found that TALE1-VP64 did not affect cell proliferation or cell cycle distribution. Taken together, our data demonstrated that TALE1-VP64 can specifically and effectively reactivate latent HIV-1 transcription, suggesting that this strategy may provide a novel approach for anti-HIV-1 latency therapy in the future.
Get full access to this article
View all access options for this article.
References
1.
KatlamaC, DeeksSG, AutranB, et al.: Barriers to a cure for HIV: New ways to target and eradicate HIV-1 reservoirs. Lancet, 2013; 381(9883):2109–2117.
2.
TyagiM and BukrinskyM: Human immunodeficiency virus (HIV) latency: The major hurdle in HIV eradication. Mol Med, 2012; 18(1):1096.
3.
Iglesias-UsselMD and RomerioF: HIV reservoirs: The new frontier. AIDS Rev, 2011; 13(1):13–29.
4.
FinziD, HermankovaM, PiersonT, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278(5341):1295–1300.
5.
SilicianoJD, KajdasJ, FinziD, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med, 2003; 9(6):727–728.
6.
ShenL and SilicianoRF: Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immun, 2008; 122(1):22–28.
7.
MarsdenMD and ZackJA: Eradication of HIV: Current challenges and new directions. J Antimicrob Chemother, 2009; 63(1):7–10.
8.
RichmanDD, MargolisDM, DelaneyM, et al.: The challenge of finding a cure for HIV infection. Science, 2009; 323(5919):1304–1307.
9.
BartonKM, BurchBD, Soriano-SarabiaN, et al.: Prospects for treatment of latent HIV. Clin Pharmacol Ther, 2012; 93(1):46–56.
10.
KerrJS, GallowayS, LagruttaA, et al.: Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol, 2010; 29(1):3–19.
11.
MatalonS, RasmussenTA, and DinarelloCA: Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med, 2011; 17(5–6):466.
12.
PionM, JordanA, BiancottoA, et al.: Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation. J Virol, 2003; 77(7):4025–4032.
13.
MillerJC, TanS, QiaoG, et al.: A TALE nuclease architecture for efficient genome editing. Nat Biotechnol, 2010; 29(2):143–148.
14.
RömerP, HahnS, JordanT, et al.: Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene. Science, 2007; 318(5850):645–648.
15.
KayS, HahnS, MaroisE, et al.: A bacterial effector acts as a plant transcription factor and induces a cell size regulator. Science, 2007; 318(5850):648–651.
16.
BogdanoveAJ, SchornackS, and LahayeT: TAL effectors: Finding plant genes for disease and defense. Curr Opin Plant Biol, 2010; 13(4):394–401.
17.
MoscouMJ and BogdanoveAJ: A simple cipher governs DNA recognition by TAL effectors. Science, 2009; 326(5959):1501.
18.
ScholzeH and BochJ: TAL effector-DNA specificity. Virulence, 2010; 1(5):428–432.
19.
BochJ, ScholzeH, SchornackS, et al.: Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 2009; 326(5959):1509–1512.
20.
BultmannS, MorbitzerR, SchmidtCS, et al.: Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res, 2012; 40(12):5368–5377.
21.
TremblayJP, ChapdelaineP, CoulombeZ, et al.: Transcription activator-like effector proteins induce the expression of the frataxin gene. Hum Gene Ther, 2012; 23(8):883–890.
22.
ZhangF, CongL, LodatoS, et al.: Programmable sequence-specific transcriptional regulation of mammalian genome using designer TAL effectors. Nat Biotechnol, 2011; 29(2):149.
23.
MaederML, LinderSJ, ReyonD, et al.: Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods, 2013; 10(3):243–245.
24.
Perez-PineraP, OusteroutDG, BrungerJM, et al.: Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat Methods, 2013; 10(3):239–242.
25.
CermakT, DoyleEL, ChristianM, et al.: Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res, 2011; 39(12):e82.
26.
ZhangF, CongL, LodatoS, et al.: Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol, 2011; 29(2):149–153.
27.
DingD, QuX, LiL, et al.: Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology, 2013; 440(2):182–189.
28.
QuX, WangP, DingD, et al.: Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res, 2013; 41(16):7771–7782.
29.
YingH, ZhangY, ZhouX, et al.: Selective histone deacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PloS One, 2012; 7(11):e48832.
30.
WangP, QuX, WangX, et al.: As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB. Antiviral Res, 2013; 100(3):688–697.
31.
JordanA, DefechereuxP, and VerdinE: The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J, 2001; 20(7):1726–1738.
32.
JordanA, BisgroveD, and VerdinE: HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 2003; 22(8):1868–1877.
33.
SegalDJ, GonçalvesJ, EberhardyS, et al.: Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem, 2004; 279(15):14509–14519.
34.
MoscouMJ and BogdanoveAJ: A simple cipher governs DNA recognition by TAL effectors. Science, 2009; 326(5959):1501.
35.
EberhardySR, GoncalvesJ, CoelhoS, et al.: Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol, 2006; 80(6):2873–2883.
36.
GaynorR: Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol, 1995; 193:51–77.
37.
SakaneN, KwonH-S, PagansS, et al.: Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). PLoS Pathog, 2011; 7(8):e1002184.
38.
RomaniB, EngelbrechtS, and GlashoffRH: Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol, 2010; 91(1):1–12.
39.
MarcelloA, ZoppéM, and GiaccaM: Multiple modes of transcriptional regulation by the HIV‐1 Tat transactivator. IUBMB Life, 2001; 51(3):175–181.
40.
OttM, GeyerM, and ZhouQ: The control of HIV transcription: Keeping RNA polymerase II on track. Cell Host Microbe, 2011; 10(5):426–435.
41.
SaksenaNK and PotterSJ: Reservoirs of HIV-1 in vivo: Implications for antiretroviral therapy. AIDS Rev, 2003; 5(1):3–18.
42.
SarkarI, HauberI, HauberJ, et al.: HIV-1 proviral DNA excision using an evolved recombinase. Science, 2007; 316(5833):1912–1915.
43.
EbinaH, MisawaN, KanemuraY, et al.: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep, 2013; 3:2510.
44.
MacíasD, OyaR, SanigerL, et al.: A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells. Hum Gene Ther, 2009; 20(11):1259–1268.
45.
HuelsmannPM, HofmannAD, KnoepfelSA, et al.: A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication. BMC Biotechnol, 2011; 11(1):4.
46.
WangP, QuX, WangX, et al.: Specific reactivation of latent HIV-1 with designer zinc-finger transcription factors targeting the HIV-1 5′-LTR promoter. Gene Ther, 2014; 21:491–495.
47.
GräslundT, MagnenatL, PopkovM, et al.: Exploring strategies for the design of artificial transcription factors targeting sites proximal to known regulatory regions for the induction of γ-globin expression and the treatment of sickle cell disease. J Biol Chem, 2005; 280:3707–3714.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
